Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00286-9/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=271757280&_hsenc=p2ANqtz-98Buezzd1BrWyxXaFdCs3yWjYoylSuc2tJ_C6EIiPmfNvbKXzUV3vz0fl-xOnNdbNKTggaO-nzDvMsCQP0UtC1kYU7YQ&utm_content=271743104&utm_source=hs_email